Vanda Pharmaceuticals | VNDA - Operating Profit


Vanda Pharmaceuticals reported $-40.66M in Operating Profit for its fiscal quarter ending in December of 2024.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Agios Pharmaceuticals USD -110.02M 11.55M Mar/2026
Akebia Therapeutics USD -5.45M 9.4M Dec/2025
Alnylam Pharmaceuticals USD 112.6M 24.99M Jun/2026
Anika Therapeutics USD 646K 3.88M Dec/2025
Arrowhead Research USD -170.09M 28.83M Jun/2026
AstraZeneca USD 3.16B 3.95B Jun/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Enanta Pharmaceuticals USD -23.54M 98.15M Dec/2024
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Heron Therapeutics USD 38K 3.83M Dec/2025
Insmed USD -101.31M 98.97M Jun/2026
J&J USD 6.47B 1B Sep/2026
Lexicon Pharmaceuticals USD -14.78M 2.59M Dec/2025
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Moderna USD -815M 573M Jun/2026
Novartis USD 4.24B 171M Mar/2026
Pfizer USD 667M 4.32B Jun/2026
PTC Therapeutics USD 45.89M 127.51M Mar/2026
Puma Biotechnology USD 22.08M 24.26M Sep/2024
Sangamo BioSciences USD -33.51M 12.77M Jun/2024
Sanofi EUR 2.38B 449M Jun/2026
Takeda JPY 201.42B 215.04B Jun/2026
Teva Pharmaceutical Industries USD 235M 523M Jun/2026
Ultragenyx Pharmaceutical USD -75M 141M Jun/2026
Vanda Pharmaceuticals USD -40.66M 29.66M Dec/2024
Veracyte USD 23.96M 4.88M Jun/2026